Cleo Diagnostics Bolsters FDA Submission with Access to PLCO Biobank

An announcement from CLEO Diagnostics Ltd ( (AU:COV) ) is now available.

Cleo Diagnostics Ltd has received approval from the U.S. National Cancer Institute to access blood samples from the PLCO Cancer Screening Trial biobank, a significant milestone that will bolster its FDA 510(k) submission for its Ovarian Cancer Pre-Surgical Test. This access, along with a partnership with the UKCTOCS biobank, strengthens CLEO’s clinical evidence package, enhances its regulatory strategy, and accelerates the development of its Screening Test, potentially setting a new benchmark in ovarian cancer diagnostics.

More about CLEO Diagnostics Ltd

Cleo Diagnostics Ltd is a company specializing in ovarian cancer diagnostics. It focuses on developing diagnostic tests, including a Pre-Surgical Test and a Screening Test, aimed at improving the detection and management of ovarian cancer.

Average Trading Volume: 93,780

Technical Sentiment Signal: Buy

For a thorough assessment of COV stock, go to TipRanks’ Stock Analysis page.